Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (March 2022)
27 slides from Anixa Biosciences's investor presentation, Mar 11, 2022
Slide 1: Anixa Biosciences
Aanixa BIOSCIENCES NASDAQ:ANIX March 2022 Amit Kumar, PhD Chairman and CEO ak@anixa.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Anixa Biosciences: At-a-Glance
Anixa Biosciences: At-a-Glance Anixa Biosciences is a clinical-stage company collaborating with world-renowned research Institutions to develop first-in-class treatments to prevent and treat unmet needs in oncology and infectious diseases Overview Strong Balance Sheet ¢ ~$35MM Cash, No debt NASDAQ:
Slide 4: Investment Highlights
Investment Highlights Unique, Capital Light Business Model Relies on Partnering of All Laboratory Operations with World-Class Research Centers/Iconic Academic Institutions > Technology exclusively in-licensed; programs developed by Moffitt and Cleveland Clinic > No build-out of immense fixed costs;
Slide 5: Unique Business Model: Overview
Unique Business Model: Overview Strategy: Low-Cost Business Model Key Collaborators ° Invent/in-license technology platforms o Develop technology and programs with MOFFITT vs HH Cleveland Clinic partners CANCER CENTER = Leverage existing infrastructure of partner THE = Maintain low overhead and cash
Slide 6: Anixa Business Model
Anixa Business Model Develop Technologies SSS s Technology In-license Pi n iXa aia ee license or sale FX Projects or invent BieaiCaeahoels to pharma partner ay ——————E —— PHARMA COMPANY. to Licensing Fee Milestone Payments R&D Funding Equity Investment Royalty
Slide 7: Key Benefits of Anixa Business Model
Key Benefits of Anixa Business Model Low Burn (historically ~$5 MM per year) o Requires minimal dilutive financing o Current cash can last for 4-5 years o Delays are not as detrimental Modest Staffing (4 full time employees) o Dozens of staff at partner organizations o Small headcount means fewer di
Slide 8: Four High Value Programs in Oncology and Infectious Disease
Four High Value Programs in Oncology and Infectious Disease Breast Cancer Vaccine F'} Cleveland Clinic * Immunize against a-Lactalbumin to prevent Triple Negative Breast Cancer (TNBC) and other breast cancers * Worldwide license * Cleveland Clinic collaboration for IND and clinical trials * $6.2 MM
Slide 9: Breast Cancer Vaccine Program
Aanixa BIOSCIENCES Breast Cancer Vaccine Program
Slide 10: Breast Cancer Vaccine: Retired Tissue Specific Protein
Breast Cancer Vaccine: Retired Tissue Specific Protein Inventor and PI: Vincent K. Tuohy, Ph.D. Mort and Iris November Distinguished Chair in Innovative Cancer Research, Cleveland Clinic Retired Tissue Specific Protein ¢ Expressed at periods of life, but no longer expressed as we age a, o-Lactalbumi
Slide 11: Pre-Clinical Studies: Vaccination Prevents Breast Cancer
Pre-Clinical Studies: Vaccination Prevents Breast Cancer Well-Tolerated Robust Pre-Clinical Response MMTV-neu Mice 100, “E 804 = 2 8) n 5 404 E =] 204 * Vaccinated Controls Vaccinated mice did not exhibit autoimmune ra \ damage, while single T-cell infiltrates were i : seen in non-lactating breast t
Slide 12: Breast Cancer Vaccine Trial
Breast Cancer Vaccine Trial: Conducted by Cleveland Clinic, Funded by US Department of Defense An open-label, Phase | dose-escalation trial in which successive cohorts of participants with high-risk for triple- negative breast cancer will be treated with successively higher doses of a-lactalbumin an
Slide 13: Breast Cancer Vaccine: A Significant Market Opportunity
Breast Cancer Vaccine: A Significant Market Opportunity » Prophylactic (preventative) vaccines are administered to the total eligible population » We expect reimbursement for this vaccine to be similar to the cervical cancer vaccine (~$400 retail cost) U.S. Outside U.S. (Total Eligible Population) (
Slide 14: Ovarian Cancer Vaccine Program
Aanixa BIOSCIENCES Ovarian Cancer Vaccine Program
Slide 15: Ovarian Cancer Vaccine: Retired Tissue Specific Protein
Ovarian Cancer Vaccine: Retired Tissue Specific Protein Inventor and PI: Vincent K. Tuohy, Ph.D. Mort and Iris November Distinguished Chair in Innovative Cancer Research, Cleveland Clinic Retired Tissue Specific Protein * Expressed at periods of life, but no longer expressed as we age The Extracellu
Slide 16: Profile: Ovarian Cancer Vaccine
Profile: Ovarian Cancer Vaccine Key Attributes oA\9 2 Cleveland Clinic collaboration NCI funding support via its peer-reviewed PREVENT development program PREVENT is supporting pre-clinical innovative interventions and biomarkers for cancer prevention and interception Pre-IND work is being conducted
Slide 17: Ovarian Cancer CAR-T Program
Aanixa BIOSCIENCES Ovarian Cancer CAR-T Program
Slide 18: CAR-T Technology: Background and Opportunity
CAR-T Technology: Background and Opportunity CAR- Technology has made great inroads in B-Cell cancers Our Opportunity * Durable responses (50-80% of patients) * Conventional CAR-T has not worked * Multibillion dollar valuations and big clinically in solid tumors pharma deals o Novartis - First appro
Slide 19: Anixa's Unique and Targeted CER-T Approach for Solid Tumors
Anixa’s Unique and Targeted CER-T Approach for Solid Tumors Anixa’s CAR-T Program for Ovarian Cancer Other CAR-T Programs: Novartis, JUNO, KITE and others working on B-Cell cancers Follicle Stimulating Hormone Receptor (FSHR)- mediated CAR-T Technology Chimeric Endocrine Receptor T-Cell erin Cancero
Slide 20: FSHR ONLY Expressed in Ovaries and Testes
FSHR ONLY Expressed in Ovaries and Testes *In Healthy Humans* & 0.00255 7) 7) © 0.002- a 3 a 0.0015-+ z Only in Fetal Thymus £ 0.0015 = ~ 0.0005 wu o) g ESOS Aan eh ae & SSNS POS XO SOL PH PHP LOS A 0 2 PF WPOBZ I POLL aE AF LEK SPO oF SC OK o> \ KO GPRD Ss K2) R\ om ws Rye x s Research. 2017, FSHR
Slide 21: Our FSHR-Mediated CAR-T Technology: Dual MoA
Our FSHR-Mediated CAR-T Technology: Dual MoA « Many tumors have blood vessels where FSHR is expressed even though healthy tissue does not show such expression o Physiologically, FSHR may be helpful in enabling tumors to create vasculature o Elegant target: outside of the tumor margin, FSHR on blood
Slide 22: Our FSHR-Mediated CAR-T Program: The First Potential Anti-Angiogenic CAR-T Therapy
Our FSHR-Mediated CAR-T Program: The First Potential Anti-Angiogenic CAR-T Therapy Exclusive worldwide license from The Wistar Institute We Believe Our CER-T Approach Will Work In Solid Previous Challenges: Tumors, Especially Ovarian Cancer, Where Others ° The CAR-T cells may not be susceptible to t
Slide 23: Summary: Our FSHR-Mediated CAR-T Program
Summary: Our FSHR-Mediated CAR-T Program ° Pre-clinical testing o Tested human CAR-T in immunocompromised mice against human ovarian cancer o Tested murine CAR-T in immunocompetent mice against murine ovarian cancer o Tested human CAR-T in immunocompromised mice against human breast cancer (proof-of
Slide 24: COVID-19 Therapy Program
Aanixa BIOSCIENCES COVID-19 Therapy Program
Slide 25: Covid-19 Therapy Program
Covid-19 Therapy Program: Virtual Screening & Scoring Sse" 4.2 Billion Compounds SARS-CoV-2 Enzymes ” | 5 2 m20 narration 5 Pmt 8) oe Sts et, — Hit Candidates will be synthesizea and tested in in vitro assays Current Status v Completed Initial Screening v Identified several Hit compounds v Identifie
Slide 26: Value-Creating Near-Term Milestones
Value-Creating Near-Term Milestones Breast Cancer Vaccine Ovarian Cancer Vaccine * Phase 1a trial fully enrolled ° First patient dosed in Phase 1b * Clinical data release * R&D Data release and publications * Initiate IND-enabling studies ¢ File IND application CAR-T Program Covid-19 Therapeutics °
Slide 27: Seasoned Management Team
Seasoned Management Team Chairman, Le CombiMatrix Michael J. Catelani Chief Operating Officer and Chief Financial Officer 222995 Tacere’e oe @BENITEC therapeutics Ooiorwanns snctng gs Aanixa Amit Kumar, Ph.D. President and CEO Can ea Society® p> od J RO Pamela D. Garzone, Ph.D. Chief Development Off
Anixa Biosciences — Investor Presentation (March 2022) on 6ix